Skip to content
lifestyle.travelshq.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
MapLight Therapeutics, Inc.
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
October 6, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 9, 2026
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026